Product Description
Perampanel is a potentially broad-spectrum antiepileptic drug with a novel mechanism of action that may be a useful addition for patients with epilepsy with various seizure types. The availability of novel antiepileptic drugs for epilepsy treatment enables more individualized treatment for these patients. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29953584/)
Mechanisms of Action: AMPA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, Denmark, France, Germany, India, Japan, Latvia, Spain, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Lennox Gastaut Syndrome|Seizures
Phase 2: Epilepsy|Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-002109-24 | P3 |
Active, not recruiting |
Seizures |
2028-09-07 |
|
| E2007-G000-236 | P2 |
Recruiting |
Epilepsy |
2026-12-23 |
|
| E2007-G000-236 | P2 |
Recruiting |
Epilepsy |
2026-04-06 |
|
| PR/BE/23/228 | P1 |
Completed |
Epilepsy |
2023-11-26 |